Trial criteria One-Liners
ASPIRE Aapixaban vs ASA in patients with recent ICH and Afib
CAPTIVA Severe ICAD with downstream stroke
DISCOVERY Cognitive changes post ACH, ICH or sICH
LIBREXIA Milvexian for stroke prevention after an AIS or high-risk TIA
SATURN Statin use after spontaneous lobar ICH
SleepSMART CPAP for OSA after stroke or TIA
TESTED LVO with prestroke disability (mRS>2)
VERIFY Ischemic stroke with UE weakness, able to consent.
ASPIRE

Aapixaban vs ASA in patients with recent ICH and Afib

ASPIRE— (PI: Stanton)
Indication:
ICH
Enrollment Window:
< 120 days
Age:
≥ 18
Eligibility:
  1. Have A-fib AND already be on anticoagulation for it at the time of the ICH
  2. ICH (can be multi-component ICH) or IVH
  3. Nonvalvular Afib
  4. No known allergy to aspirin or apixaban
Site(s):
UCMC
Description:
StrokeNet trial studying the use of apixaban to treat nonvalvular Afib post-ICH
Coordinator:
Jennifer Powers:
513-482-0617
ClinicalTrials.gov
NCT03907046
CAPTIVA

Severe ICAD with downstream stroke

CAPTIVA— (PI: Aziz)
Indication:
AIS
Enrollment Window:
30 days
Age:
30 - 80
Eligibility:
  1. Intracranial symptomatic stenosis (70-99%) of a major ICA
  2. mRS ≤ 4
  3. Ability to swallow pills
  4. No indication for systemic AC
Site(s):
UCMC
Description:
StrokeNet Trial: Symptomatic intracranial stenosis, 2 Stage-phase 3, Ticagrelor/ASA, Rivaroxaban/ASA vs Clopidogrel
Coordinator:
Marchele Nowell-Bostic:
513-328-1606
ClinicalTrials.gov
NCT05047172

DISCOVERY

Cognitive changes post ACH, ICH or sICH

DISCOVERY — (PI: Demel)
Indication:
Ischemic Stroke, ICH, aSAH
Enrollment Window:
< 6 weeks
Age:
≥ 18
Eligibility:
  1. All strokes confirmed on MRI or CT
  2. No hx dementia
Site(s):
UCMC
Description:
The DISCOVERY is investigating the mechanisms of post-stroke cognitive impairment and dementia to develop potential targets for personalized medicine and dramatically reduce the rates of cognitive and functional disability in high-risk US populations
Coordinators:
Jennifer Powers:
513-482-0617
Ranjaka Gunawardena:
513-884-3260
ClinicalTrials.gov
NCT04916210

LEEDERS

Milvexian for stroke prevention after an AIS or high-risk TIA

LEEDERS — (PI: Krekler)
Indication:
AIS
Enrollment Window:
3 – 6 months
Age:
≥ 18
Eligibility:
  1. Adults who have had an AIS
  2. Difficulty swallowing
  3. No history of other neurological conditions
Site(s):
UCMC
Description:
Speech Path trial looking at patients post stroke with issues with dysphagia and at home tongue endurance exercises
Coordinators:
Anna Hopkins / Claudia Vollman:
513-558-4152
ClinicalTrials.gov
NA

SATURN

Statin use after spontaneous lobar ICH

SATURN — (PI: Stanton)
Indication:
ICH
Enrollment Window:
< 7 days
Age:
≥ 50
Eligibility:
  1. Spontaneous lobar ICH within 7d of onset
  2. Taking a statin drug at the time of ICH onset
Site(s):
UCMC
Description:
StrokeNET trial: comparing discontinuation or continuation of statins
Coordinators:
Jennifer Powers:
513-482-0617
ClinicalTrials.gov
NCT03936361

SleepSMART

CPAP for OSA after stroke or TIA

SleepSMART — (PI: Kreitzer)
Indication:
Ischemic Stroke
Enrollment Window:
< 7 days
Age:
≥ 18
Eligibility:
  1. Ischemic stroke with NIHSS of 1
  2. No current use of CPAP within 1 month
Site(s):
West Chester, UCMC, Christ
Description:
StrokeNET trial: OSA in acute stroke and use of CPAP for treatment
Coordinators:
Ranjaka Gunawardena: 513-884-3260
Jennifer Powers:
513-482-0617
ClinicalTrials.gov
NCT05016960

TESTED

LVO with prestroke disability (mRS>2)

TESTED — (PI: Demel)
Indication:
AIS (anterior circulation LVO)
Enrollment Window:
Within 5 days of hospital admission
Age:
≥ 18
Eligibility:
  1. Anterior circulation LVO (intracranial ICA, M1 or dominant M2)
  2. mRS 3-4, NIHSS ≥ 6
  3. ASPECTS ≥ 3
  4. Do NOT have to get EVT to qualify
Site(s):
UCMC
Description:
PCORI-funded trial comparing the effectiveness of EVT to medical management in patients with LVO and pre-stroke disability
Coordinators:
Jennifer Powers:
513-482-0617
ClinicalTrials.gov
NCT05911568

VERIFY

Ischemic stroke with UE weakness, able to consent

VERIFY — (PI: Boyne)
Indication:
Ischemic Stroke
Enrollment Window:
48 – 96 hrs
Age:
≥ 18
Eligibility:
  1. Adult participants within 24-96 hours of acute stroke onset; unilateral stroke due to ischemia or ICH
  2. Upper arm weakness
Site(s):
UCMC
Description:
StrokeNET trial: Validate biomarkers of upper extremity motor outcome in acute stroke window for immediate use in clinical trials
Coordinators:
Colin Drury:
513-558-7676
ClinicalTrials.gov
NCT05338697